BioXcell--InVivoPlus rat IgG2a isotype control同型对照

BioXcell--InVivoPlus rat IgG2a isotype control同型对照

产品描述：

BioXcell 欣博盛生物 InVivoPlus rat IgG2a isotype control克隆号为2A3的同型对照抗体与三硝基苯酚反应。因为哺乳动物不表达三硝基苯酚，因此该抗体非常适合在大多数体内和体外应用中用作大鼠IgG2a抗体的同型对照。

产品详情：

产品名称	InVivoPlus rat IgG2a isotype control
产品货号	BP0089
产品规格	5/25/50/100mg
克隆号	2A3
同种型	Rat IgG2a, κ
产品形式	PBS, pH 6.5,Contains no stabilizers or preservatives
纯度	>95%, Determined by SDS-PAGE
聚合	<5%, Determined by SEC
无菌处理	0.2 µm filtration
纯化方式	Protein G
RRID	AB_1107769
分子量	150 kDa
小鼠病原检测	Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative
保存条件	抗体原液保存在4°C，不能冷冻保存。
推荐同型对照	InVivoMAb rat IgG2a isotype control, anti-trinitrophenol（货号BE0089）
推荐抗体稀释液	InVivoPure pH 6.5 Dilution Buffer（货号IP0065）

为什么选择InVivoPlus抗体？

InVivoPlus级别的产品内毒素含量更低，经过多种实验验证，更适合用于体内实验研究

该产品自上市已被多篇SCI文献引用，品质有保证，以下是部分已发表的文献引用：

文章

1.Bauche, D., et al. (2018). 'LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis' Immunity 49(2): 342-352 e345.

2.Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.

3.Dai, M., et al. (2015). 'Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies' Clin Cancer Res 21(5): 1127-1138.

4.Kurtulus, S., et al. (2015). 'TIGIT predominantly regulates the immune response via regulatory T cells' J Clin Invest. doi : 10.1172/JCI81187.

5.Ellis, G. T., et al. (2015). 'TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection' EMBO Rep 16(9): 1203-1218.